SCOPUS 정보 검색 플랫폼

Volumn 19, Issue 3, 2001, Pages 239-243

Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy: A Southwest Oncology Group study

(8) Whitehead, Robert P a Unger, Joseph M b Flaherty, Lawrence E c Eckardt, John R d Taylor, Sarah A e Didolkar, Mukund S f Samlowski, Wolfram g Sondak, Vernon K h

a UNIVERSITY OF TEXAS MEDICAL BRANCH (United States)

b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER (United States)

c WAYNE STATE UNIVERSITY (United States)

d St Louis Cape Girardeau CCOP (United States)

e UNIVERSITY OF KANSAS MEDICAL CENTER (United States)

f TEMPLE UNIVERSITY (United States)

g UNIVERSITY OF UTAH HEALTH SCIENCES CENTER (United States)

h UNIVERSITY OF MICHIGAN (United States)

Author keywords

CI 980; Melanoma; Phase II trial

Indexed keywords

GLYCOPROTEIN P; MIVOBULIN ISETHIONATE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; DISSEMINATED CANCER; DRUG CYTOTOXICITY; DRUG INFUSION; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MALAISE; MALE; MELANOMA; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL LINE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PYRAZINES; PYRIDINES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034857890 PISSN: 01676997 EISSN: None Source Type: Journal
DOI: 10.1023/A:1010624702340 Document Type: Article

Times cited : (7)

References (14)

1
- 0003077969
- Cutaneous melanoma
- Ch. 41.2. DeVita VT Jr., Hellman S, Rosenberg SA (Eds). Lippincott-Raven Publishers, Philadelphia
- (1997) Cancer: Principles and Practice of Oncology. 5th Edn.
- Balch, C.M.¹ Reintgen, D.S.² Kirkwood, J.M.³ Houghton, A.⁴ Peters, L.⁵ Ang, K.K.⁶

2
- 0032858487
- Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma
- (1999) J Clin Oncol , vol.17 , pp. 2745-2751
- Chapman, P.B.¹ Einhorn, L.H.² Meyers, M.L.³ Saxman, S.⁴ Destro, A.N.⁵ Panageas, K.S.⁶ Begg, C.B.⁷ Agarwalla, S.S.⁸ Schuchter, L.M.⁹ Ernstoff, M.S.¹⁰ Houghton, A.N.¹¹ Kirkwood, J.M.¹²

3
- 0020079714
- Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-l,2-dihydro-3-[(N-methylanilino)methyl]-pyridol [3,4-b] pyrazin-7-ylcarbamate (NSC 181928)
- (1982) Cancer Res , vol.42 , pp. 791-798
- Wheeler, G.P.¹ Bowdon, B.J.² Werline, J.A.³ Adamson, D.J.⁴ Temple, C.G.⁵

4
- 0020624384
- Biological effects and structure - Activity relationships of 1,2-dihydropyrido [3,4-b] pyrazines
- (1983) Cancer Res , vol.43 , pp. 3567-3575
- Wheeler, G.P.¹ Bowdon, B.J.² Temple C., Jr.³ Adamson, D.J.⁴ Webster, J.⁵

5
- 0023139279
- Comparison of 1,2-dihydropyrido [3,4-b] pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis
- (1987) Cancer Res , vol.47 , pp. 1621-1626
- Bowdon, B.J.¹ Waud, W.R.² Wheeler, G.P.³ Hain, R.H.⁴ Dansby, L.⁵ Temple, C.G.⁶

6
- 0003860941
- (1990) Investigator's Brochure

7
- 0025297395
- Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyridol [3,4-b] pyrazin-7-ylcarbamate, 2 hydroxyeth-anesulfonate hydrate (NSC 370147) against selected tumor systems in culture and in mice
- (1990) Cancer Res , vol.50 , pp. 3239-3244
- Waud, W.R.¹ Leopold, W.R.² Elliot, W.L.³ Dykes, D.J.⁴ Laster W.R., Jr.⁵ Temple C.G., Jr.⁶ Harrison S.D., Jr.⁷ Griswold D.P., Jr.⁸

8
- 0003931347
- Antitumor activity of novel 1,2-dihydropyrido [3,4-b]-pyrazine in preclinical drug-sensitive and resistant tumors
- (1986) Proc Am Ass Cancer Res , vol.27 , pp. 306
- Griswold D.P., Jr.¹ Temple C.G., Jr.² Trader, M.W.³ Leopold III, W.R.⁴ Laster W.R., Jr.⁵ Dykes, D.J.⁶

9
- 0030887268
- Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent
- (1997) Clin Cancer Res , vol.3 , pp. 401-407
- Rowinsky, E.K.¹ Long, G.S.² Noe, D.A.³ Grochow, L.B.⁴ Bowling, M.K.⁵ Sartorius, S.E.⁶ Donehower, R.C.⁷

10
- 0028044792
- Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863
- (1994) Cancer Res , vol.54 , pp. 75-84
- De Ines, C.¹ Leynadier, D.² Barasoain, I.³ Peyrot, V.⁴ Garcia, P.⁵ Briand, C.⁶ Rener, G.A.⁷ Temple C., Jr.⁸

11
- 0030725152
- Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity
- (1997) Am J Clin Oncol , vol.20 , pp. 573-576
- Pazdur, R.¹ Meyers, C.² Diaz-Canton, E.³ Abbruzzese, J.L.⁴ Patt, Y.⁵ Grove, W.⁶ Ajani, J.⁷

12
- 0031871874
- Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas
- (1998) Invest New Drugs , vol.16 , pp. 87-92
- Patel, S.R.¹ Burgess, M.A.² Papadopolous, N.E.³ Sidhu, G.⁴ Gray, R.⁵ Plager, C.⁶ Jenkins, J.⁷ Benjamin, R.S.⁸

13
- 15444354410
- Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma
- (1998) Anti Cancer Drugs , vol.9 , pp. 405-409
- Kudelka, A.P.¹ Hasenburg, A.² Verschraegen, C.F.³ Edwards, C.L.⁴ Meyers, C.A.⁵ Varma, D.⁶ Freedman, R.S.⁷ Forman, A.⁸ Conrad, C.A.⁹ Grove, W.¹⁰ Grothey, A.¹¹ Kavanagh, J.J.¹²

14
- 0343356534
- In vivo evaluation of the potential for therapeutic synergy between CI-980 and standard chemotherapeutic agents
- abstract
- (1993) Proceedings AACR , vol.34 , pp. 296
- Leopold, W.R.¹ Elliott, W.L.² Pryzbranowski, S.A.³ Waud, W.R.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.